Furthermore, Patel et al.46 have described a novel high-throughput screen that identified idarubicin, a small molecule capable of augmenting the IFN signalling pathway in vitro leading to increased ISG induction; however, this molecule has yet to be tested in vivo. The ability to identify molecules with IFN-augmenting characteristics in a high-throughput, biologically relevant screen and confirm action in primary cells is thus a powerful tool for drug discovery and may provide future novel therapies for the treatment of RV-associated asthma exacerbations as well as other viral infections. Here, IFNA1 is linked to asthma.